M1974 Clinicopathological Characteristics of Barrett's Esophageal Cancer in Japanese Patients and Long-Term Results of Therapy

Summary At our hospital, the main treatment for resectable esophageal cancer (EC) has since 2013 been total minimally invasive esophagectomy (TMIE). The aim of this study was to present the short- and long-term results in patients operated with TMIE. This cross-sectional study includes all patients scheduled for TMIE from June 2013 to January 2016 at Oslo University Hospital. Data on morbidity, mortality, and survival were retrospectively collected from the patient administration system and the Norwegian Cause of Death Registry. Long-term postoperative health-related quality of life (HRQL) and level of dysphagia were assessed by patients completing the following questionaries: EORTC QLQ-OG25, QLQ-C30, and the Ogilvie grading scale. A total of 123 patients were included in this study with a median follow-up time of 58 months (1–88 months). 85% had adenocarcinoma, 15% squamous cell carcinoma. Seventeen patients (14%) had T1N0M0, 68 (55%) T2-T3N0M0, or T1-T2N1M0 and 38 (31%) had either T3N1M0 or T4anyNM0. Ninety-eight patients (80%) received neoadjuvant (radio)chemotherapy and 104 (85%) had R0 resection. Anastomotic leak rate and 90-days mortality were 14% and 2%, respectively. The 5-year overall survival was 53%. Patients with tumor free resection margins of >1 mm (R0) had a 5-year survival of 57%. Median 60 months (range 49–80) postoperatively the main symptoms reducing HRQL were anxiety, chough, insomnia, and reflux. Median Ogilvie score was 0 (0–1). In this study, we report relatively low mortality and good overall survival after TMIE for EC. Moreover, key symptoms reducing long-term HRQL were identified.

Download Full-text

Leiomyoma of the Esophagus

Tumori Journal ◽

10.1177/030089168607200509 ◽

1986 ◽

Vol 72 (5) ◽

pp. 503-506 ◽

Cited By ~ 4

Author(s):

Ferdinando Preda ◽

Marco Alloisio ◽

Cosimo Lequaglie ◽

Mauro Ongari ◽

Gianluigi Ravasi

Keyword(s):

Esophageal Cancer ◽

Differential Diagnosis ◽

Preoperative Diagnosis ◽

Long Term Results ◽

Barium Swallow ◽

Thoracic Esophagus ◽

Esophageal Leiomyoma ◽

Correct Preoperative Diagnosis ◽

Clinical Records

A review of the clinical records from 1947 to 1984 of the Istituto Nazionale Tumori of Milan provided 20 cases (14 males and 6 females) of esophageal leiomyoma. Eighteen of the tumors were in the thoracic esophagus and 2 were at the cardiac level. The most frequent symptoms were dysphagia, slight epigastralgia and odynophagia. Differential diagnosis should be made with mediastinic neoplasms and esophageal cancer. Barium swallow and esophagoscopy are the most sensitive procedures for a correct preoperative diagnosis. Surgery is mandatory because of the tendency to a continuous endoluminal growth (in 97% of the cases) and a possible malignant transformation. However, surgery is conservative: extramucosal enucleation of the leiomyoma is the procedure of choice. The long-term results are excellent, and morbidity is acceptable.

Download Full-text

Treatment of Resectable Esophageal Cancer: Indications and Long-term Results

Updates in Surgery - Treatment of Esophageal and Hypopharyngeal Squamous Cell Carcinoma ◽

10.1007/978-88-470-2330-7_14 ◽

2012 ◽

pp. 161-181

Author(s):

Giovanni de Manzoni ◽

Andrea Zanoni ◽

Jacopo Weindelmayer

Keyword(s):

Esophageal Cancer ◽

Long Term Results ◽

Resectable Esophageal ◽

Resectable Esophageal Cancer

Download Full-text

Long‐term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer

Cancer Science ◽

10.1111/cas.14380 ◽

2020 ◽

Vol 111 (5) ◽

pp. 1676-1684 ◽

Cited By ~ 2

Author(s):

Ken Kato ◽

Yuichiro Doki ◽

Takashi Ura ◽

Yasuo Hamamoto ◽

Takashi Kojima ◽

...

Keyword(s):

Esophageal Cancer ◽

Japanese Patients ◽

Term Efficacy

Download Full-text

Long-Term Results of Aortic Valve Replacement With Mechanical Prosthesis or Carpentier-Edwards Perimount Bioprosthesis in Japanese Patients According to Age

Circulation Journal ◽

10.1253/circj.cj-14-0466 ◽

2014 ◽

Vol 78 (11) ◽

pp. 2688-2695 ◽

Cited By ~ 19

Author(s):

Takahiro Nishida ◽

Hiromichi Sonoda ◽

Yasuhisa Oishi ◽

Hideki Tatewaki ◽

Yoshihisa Tanoue ◽

...

Keyword(s):

Aortic Valve ◽

Aortic Valve Replacement ◽

Valve Replacement ◽

Japanese Patients ◽

Long Term Results ◽

Mechanical Prosthesis

Download Full-text

Long term results and patterns of recurrence from SCOPE 1: A phase II/III randomised trial of definitive chemoradiotherapy (dCRT) plus or minus cetuximab (dCRT+C) in esophageal cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.4_suppl.118 ◽

2016 ◽

Vol 34 (4_suppl) ◽

pp. 118-118 ◽

Cited By ~ 1

Author(s):

Somnath Mukherjee ◽

Chris Hurt ◽

Stephen Falk ◽

Simon Gollins ◽

John Staffurth ◽

...

Keyword(s):

Esophageal Cancer ◽

Phase Ii ◽

Randomised Trial ◽

Multivariable Analysis ◽

Dose Intensity ◽

Long Term Results ◽

Full Dose ◽

Number Of Patients ◽

Patterns Of Recurrence

118 Background: One of the largest trials in dCRT for localised oesophageal cancer, SCOPE 1 tested the role of adding cetuximab to conventional dCRT, and showed that this was associated with greater toxicity and worse survival. Here we present the long-term outcomes. Methods: Phase II/III trial. Randomisation: cisplatin 60mg/m2 D1 and capecitabine 625mg/m2 daily D1-21 for 4 cycles with/without Cetuximab 400mg/m2 D1 followed by 250mg/m2weekly. RT: 50Gy in 25 fractions given concurrent with cycles 3 and 4. Recruitment: Feb 2008 - Feb 2012, when the IDMC recommended trial closure on the basis of futility. Results: 258 patients (dCRT = 129; dCRT+C = 129) were recruited from 36 centres. Median follow-up (IQR): 46.7 (36.0-49.0) months for all surviving pts. 65.1% (dCRT arm) and 69.8% (dCRT+C arm) of patients had died. Esophageal cancer was the cause in 82.1% and 86.7% of deaths respectively (p = 0.41). Median OS months (95% CI) was 34.5 (24.7-42.3) in dCRT and 24.7 (18.6-31.3) in dCRT+C (HR 1.25, p = 0.137); corresponding 3-year OS (95% CI) was 47.2% (38.2%-55.7%) and 37.6% (29.1%-46.0%). Median PFS (95% CI): 24.1 (15.3-29.9) and 15.9 (10.7-20.8) months respectively (HR1.28, p = 0.114). There was some evidence that local PFS (within RT field) was lower in the dCRT+C arm (HR1.38, p = 0.051). On multivariable analysis including treatment arm, Stage I-II ds (vs Stage III), full-dose RT and higher cisplatin dose intensity ( ≥ 75% vs < 75%) were associated with improved OS and PFS. Patterns of recurrence (n [%]) were similar in both arms (see table). In dCRT arm, 31/38 pts (81.6%) with local relapse within the RT field compared to 40/48 (83.3%) in the dCRT+C arm (p = 0.8). Conclusions: The mature analysis shows unprecedented survival in dCRT arm, comparable to surgical trials (e.g. 3-year OS % [95% CIs] in OE05: CF 39 [35, 44] and ECX 42 [37, 46], in OE02: 31 [27, 36]). OS inferiority of dCRT+C is no longer statistically significant. The lower PFS (within RT field) in the dCRT+C arm was consistent with the lower number of patients receiving full dose of RT in the dCRT+C arm. Clinical trial information: 47718479. [Table: see text]

Download Full-text